Denali Therapeutics Total Current Liabilities

Denali Therapeutics (DNLI) currently reports a total current liabilities of $110M as of March 2026. That compares with $92M in the prior-year period — up 19.9% year over year. Use the charts on this page to explore Denali Therapeutics's total current liabilities history and peer comparisons.

Denali Therapeutics's total current liabilities increased from $92M to $110M — a 19.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Denali Therapeutics reported $110M in total current liabilities as of March 2026. That compares with $92M in the prior-year period — up 19.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $110M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Denali Therapeutics, and consider following DNLI for alerts when major investors trade the stock.

Denali Therapeutics is classified in the Healthcare sector. On total current liabilities, it currently shows $110M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNLI with unrelated industries.